GAMMA Investing LLC Makes New Investment in Nevro Corp. (NYSE:NVRO)

GAMMA Investing LLC acquired a new position in shares of Nevro Corp. (NYSE:NVRO) in the 1st quarter, Holdings Channel.com reports. The firm acquired 6,716 shares of the medical equipment provider’s stock, valued at approximately $39,000.

Other institutional investors also recently modified their holdings of the company. Amundi acquired a new position in shares of Nevro during the 4th quarter worth about $30,000. Oxford Asset Management LLP acquired a new position in shares of Nevro during the 4th quarter worth about $39,000. Corton Capital Inc. acquired a new position in shares of Nevro during the 4th quarter worth about $43,000. Headlands Technologies LLC acquired a new position in shares of Nevro during the 4th quarter worth about $45,000. Finally, Ieq Capital LLC acquired a new position in shares of Nevro during the 4th quarter worth about $46,000. 95.52% of the stock is currently owned by institutional investors and hedge funds.

Nevro Price Performance

Shares of NVRO opened at $5.85 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 3.76 and a current ratio of 5.02. The stock has a 50 day simple moving average of $5.85 and a 200 day simple moving average of $5.35. Nevro Corp. has a 52-week low of $3.17 and a 52-week high of $10.37. The firm has a market capitalization of $224.32 million, a PE ratio of -3.09 and a beta of 0.81.

Analyst Ratings Changes

Separately, Wall Street Zen initiated coverage on Nevro in a research report on Saturday, May 17th. They set a “hold” rating for the company. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $5.36.

About Nevro

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.